The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed. But even before then, the roadmap gave researchers the opportunity to develop gene therapies to correct genetic abnormalities.
Gene editing, which seeks to directly alter a patient’s genome itself, is the next stage. If successful, it may provide a viable treatment for many previously untreatable genetic disorders. That is why getting in on the ground floor of these top three biotech stocks could be so beneficial for long-term investors.
This post originally appeared at InvestorPlace.